D-0516-2019 Class III Terminated

Recalled by Amerigen Pharmaceuticals Inc. — Lyndhurst, NJ

FDA drug recall D-0516-2019 was initiated by Amerigen Pharmaceuticals Inc. on Feb 19, 2019 and is designated Class III. Reason for recall: Failed dissolution specifications The recall status is terminated (terminated Dec 17, 2019). Affected quantity: a) 2,413 bottles b) 3,355 bottles.

Recall details

Product Type
Drugs
Report Date
Feb 27, 2019
Initiation Date
Feb 19, 2019
Termination Date
Dec 17, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
a) 2,413 bottles b) 3,355 bottles

Product description

Temozolomide Capsules, 5 mg, packaged in a) 5-count bottle (NDC 43975-252-05) b) 14-count bottle (NDC 43975-252-14), Rx only, Mfd. by: Stason Pharmaceuticals, Inc., Irvine, CA 92618, Dist. By: Amerigen Pharmaceuticals, Lyndhurst, NJ 07071

Reason for recall

Failed dissolution specifications

Distribution pattern

Product was distributed to 4 wholesalers/distributors and 1 retail account who may have further distribute the product throughout the United States.

Code information

Lot #: a) 18J043A, Exp 09/30/2020, b) 18J043B, Exp 09/30/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0516-2019
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0516-2019. Report a data issue: hello@regdatalab.com.